DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) insider Scott Praill acquired 17,500 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was acquired at an average price of $0.85 per share, for a total transaction of $14,875.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of DelMar Pharmaceuticals, Inc. (DMPI) traded down 1.39% during mid-day trading on Thursday, hitting $0.88. The company had a trading volume of 915,810 shares. The stock’s market cap is $18.96 million. DelMar Pharmaceuticals, Inc. has a 52-week low of $0.80 and a 52-week high of $6.00. The stock’s 50-day moving average is $1.14 and its 200-day moving average is $2.18.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/05/delmar-pharmaceuticals-inc-dmpi-insider-buys-14875-00-in-stock.html.

A number of research analysts have recently commented on DMPI shares. HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 24th. Maxim Group reiterated a “buy” rating and issued a $11.00 price objective on shares of DelMar Pharmaceuticals in a report on Friday, June 23rd. Finally, Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th.

A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Franklin Resources Inc. acquired a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 13.74% of the stock is currently owned by institutional investors and hedge funds.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.